{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:21:29Z","timestamp":1760300489234,"version":"build-2065373602"},"reference-count":51,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Tackling antimicrobial resistance (AMR) represents a social responsibility aimed at renewing the antimicrobial armamentarium and identifying novel therapeutical approaches. Among the possible strategies, efflux pumps inhibition offers the advantage to contrast the resistance against all drugs which can be extruded. Efflux pump inhibitors (EPIs) are molecules devoid of any antimicrobial activity, but synergizing with pumps-substrate antibiotics. Herein, we performed an in silico scaffold hopping approach starting from quinolin-4-yloxy-based Staphylococcus aureus NorA EPIs by using previously built pharmacophore models for NorA inhibition activity. Four scaffolds were identified, synthesized, and modified with appropriate substituents to obtain new compounds, that were evaluated for their ability to inhibit NorA and synergize with the fluoroquinolone ciprofloxacin against resistant S. aureus strains. The two quinoline-4-carboxamide derivatives 3a and 3b showed the best results being synergic (4-fold MIC reduction) with ciprofloxacin at concentrations as low as 3.13 and 1.56 \u00b5g\/mL, respectively, which were nontoxic for human THP-1 and A549 cells. The NorA inhibition was confirmed by SA-1199B ethidium bromide efflux and checkerboard assays against the isogenic pair SA-K2378 (norA++)\/SA-K1902 (norA-). These in vitro results indicate the two compounds as valuable structures for designing novel S. aureus NorA inhibitors to be used in association with fluoroquinolones.<\/jats:p>","DOI":"10.3390\/ijms21197037","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T08:33:03Z","timestamp":1600936383000},"page":"7037","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Structural Modifications of the Quinolin-4-yloxy Core to Obtain New Staphylococcus aureus NorA Inhibitors"],"prefix":"10.3390","volume":"21","author":[{"given":"Rolando","family":"Cannalire","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Perugia, via del Liceo 1, 06123 Perugia, Italy"},{"name":"Department of Pharmacy, University of Napoli \u201cFederico II\u201d, via D. Montesano 49, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-5879","authenticated-orcid":false,"given":"Gianmarco","family":"Mangiaterra","sequence":"additional","affiliation":[{"name":"Department of Life and Environmental Sciences, Universit\u00e0 Politecnica delle Marche, via Brecce Bianche, 60131 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-8564","authenticated-orcid":false,"given":"Tommaso","family":"Felicetti","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Perugia, via del Liceo 1, 06123 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Astolfi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Perugia, via del Liceo 1, 06123 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Cedraro","sequence":"additional","affiliation":[{"name":"Department of Life and Environmental Sciences, Universit\u00e0 Politecnica delle Marche, via Brecce Bianche, 60131 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9992-6318","authenticated-orcid":false,"given":"Serena","family":"Massari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Perugia, via del Liceo 1, 06123 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Manfroni","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Perugia, via del Liceo 1, 06123 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana","family":"Tabarrini","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Perugia, via del Liceo 1, 06123 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0160-1022","authenticated-orcid":false,"given":"Salvatore","family":"Vaiasicca","sequence":"additional","affiliation":[{"name":"Department of Life and Environmental Sciences, Universit\u00e0 Politecnica delle Marche, via Brecce Bianche, 60131 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3530-5042","authenticated-orcid":false,"given":"Maria Letizia","family":"Barreca","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Perugia, via del Liceo 1, 06123 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violetta","family":"Cecchetti","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Perugia, via del Liceo 1, 06123 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-2227","authenticated-orcid":false,"given":"Francesca","family":"Biavasco","sequence":"additional","affiliation":[{"name":"Department of Life and Environmental Sciences, Universit\u00e0 Politecnica delle Marche, via Brecce Bianche, 60131 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0971-3536","authenticated-orcid":false,"given":"Stefano","family":"Sabatini","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Perugia, via del Liceo 1, 06123 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"unstructured":"WHO (2016). Antimicrobial Resistance: Global Report on Surveillance 2014, WHO.","key":"ref_1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/IDR.S173867","article-title":"Antibiotic resistance: A rundown of a global crisis","volume":"11","author":"Aslam","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41579-020-0378-z","article-title":"Evolutionary causes and consequences of bacterial antibiotic persistence","volume":"18","author":"Bakkeren","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/dkx502","article-title":"Actual versus \u2018ideal\u2019 antibiotic prescribing for common conditions in English primary care","volume":"73","author":"Pouwels","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/jms.jms_25_17","article-title":"World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","volume":"32","author":"Shrivastava","year":"2018","journal-title":"J. Med. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"eaau4679","DOI":"10.1126\/science.aau4679","article-title":"The challenge of antimicrobial resistance: What economics can contribute","volume":"364","author":"Roope","year":"2019","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd2226","article-title":"The antibacterial drugs market","volume":"6","author":"Kresse","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/acsinfecdis.7b00071","article-title":"The Challenge of Overcoming Antibiotic Resistance: An Adjuvant Approach?","volume":"3","author":"Melander","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd4675","article-title":"Antibiotic resistance breakers: Can repurposed drugs fill the antibiotic discovery void?","volume":"14","author":"Brown","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tim.2016.06.009","article-title":"Antibiotic Adjuvants: Rescuing Antibiotics from Resistance","volume":"24","author":"Wright","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijantimicag.2007.10.025","article-title":"Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: Mechanisms for their direct and indirect activities","volume":"31","author":"Martins","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrd3013","article-title":"Anti-virulence strategies to combat bacteria-mediated disease","volume":"9","author":"Rasko","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1021\/acs.jmedchem.7b00215","article-title":"Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms","volume":"60","author":"Schillaci","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41579-018-0048-6","article-title":"Multidrug efflux pumps: Structure, function and regulation","volume":"16","author":"Du","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"D181","DOI":"10.1093\/nar\/gkj001","article-title":"TCDB: The Transporter Classification Database for membrane transport protein analyses and information","volume":"34","author":"Saier","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/AAC.37.1.128","article-title":"Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter","volume":"37","author":"Neyfakh","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003495-200464020-00004","article-title":"Efflux-Mediated Drug Resistance in Bacteria","volume":"64","author":"Li","year":"2004","journal-title":"Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2475067","article-title":"Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens","volume":"2016","author":"Santajit","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/med.21591","article-title":"Efflux pump inhibitors of clinically relevant multidrug resistant bacteria","volume":"39","author":"Lamut","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1021\/acs.jmedchem.5b01219","article-title":"Indole Based Weapons to Fight Antibiotic Resistance: A Structure\u2013Activity Relationship Study","volume":"59","author":"Lepri","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/acs.jmedchem.6b01281","article-title":"Improved Potency of Indole-Based NorA Efflux Pump Inhibitors: From Serendipity toward Rational Design and Development","volume":"60","author":"Buonerba","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/cmdc.201400042","article-title":"1-(1H-Indol-3-yl) ethanamine derivatives as potent Staphylococcus aureus NorA efflux pump inhibitors","volume":"9","author":"Hequet","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1021\/acs.jmedchem.8b00791","article-title":"2-PhenylquinolineS. Aureus NorA Efflux Pump Inhibitors: Evaluation of the Importance of Methoxy Group Introduction","volume":"61","author":"Felicetti","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/14756366.2020.1719083","article-title":"C-2 phenyl replacements to obtain potent quinoline-based Staphylococcus aureus NorA inhibitors","volume":"35","author":"Felicetti","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1021\/jm401808n","article-title":"First Identification of Boronic Species as Novel Potential Inhibitors of the Staphylococcus aureus NorA Efflux Pump","volume":"57","author":"Fontaine","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2015.02.056","article-title":"Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: Study of 6-substituted pyridine-3-boronic acid derivatives","volume":"95","author":"Fontaine","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1016\/j.bmc.2012.05.025","article-title":"Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles","volume":"20","author":"Holler","year":"2012","journal-title":"Bioorganic Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jac\/dkn088","article-title":"Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus","volume":"61","author":"Kumar","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9847","DOI":"10.1016\/j.bmc.2008.09.042","article-title":"Piperine analogs as potent Staphylococcus aureus NorA efflux pump inhibitors","volume":"16","author":"Sangwan","year":"2008","journal-title":"Bioorgan. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1021\/jm200370y","article-title":"Evolution from a Natural Flavones Nucleus to Obtain 2-(4-Propoxyphenyl) quinoline Derivatives as potent inhibitors of the S. Aureus NorA Efflux Pump","volume":"54","author":"Sabatini","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.41.12.2733","article-title":"Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus","volume":"41","author":"Kaatz","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1021\/acs.jmedchem.6b01439","article-title":"Pharmacophore-Based Repositioning of Approved Drugs as NovelStaphylococcus aureusNorA Efflux Pump Inhibitors","volume":"60","author":"Astolfi","year":"2017","journal-title":"J. Med. Chem."},{"unstructured":"(2020, July 01). Prestwick Chemical. Available online: http:\/\/www.prestwickchemical.com\/libraries-screening-lib-drug-frag.html.","key":"ref_36"},{"doi-asserted-by":"crossref","unstructured":"(2017). Schr\u00f6dinger Release 2017-2: Core Hopping, Schr\u00f6dinger, LLC.","key":"ref_37","DOI":"10.2307\/j.ctvcm4h07.63"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1747-0285.2006.00384.x","article-title":"Phase: A novel approach to pharmacophore modeling and 3D database searching","volume":"67","author":"Dixon","year":"2006","journal-title":"Chem. Boil. Drug Des."},{"doi-asserted-by":"crossref","unstructured":"(2017). Schr\u00f6dinger Release 2017-2: Phase, Schr\u00f6dinger, LLC.","key":"ref_39","DOI":"10.2307\/j.ctvcm4h07.63"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bmc.2017.12.048","article-title":"Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide","volume":"26","author":"Liao","year":"2018","journal-title":"Bioorgan. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/jm101346r","article-title":"Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase","volume":"54","author":"Prime","year":"2011","journal-title":"J. Med. Chem."},{"unstructured":"Smith, N., Bonnefous, C., Govek, S.P., Wu, D., Pinkerton, A.B., Kahraman, M., Cook, T., Noble, S.A., Borchardt, A.J., and Prins, T. (2009). Heterocyclic Modulators of gpr119 for Treatment of Disease. (Application No. PCT\/US2009\/061281).","key":"ref_42"},{"key":"ref_43","first-page":"1149","article-title":"Genetic analysis of epidermin biosynthetic genes and epidermin-negative mutants of Staphylococcus epidermidis","volume":"204","author":"Augustin","year":"1992","journal-title":"JBIC J. Boil. Inorg. Chem."},{"doi-asserted-by":"crossref","unstructured":"(2017). Schr\u00f6dinger Release 2017-2: LigPrep, Schr\u00f6dinger, LLC.","key":"ref_44","DOI":"10.2307\/j.ctvcm4h07.63"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10822-010-9349-1","article-title":"Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution","volume":"24","author":"Greenwood","year":"2010","journal-title":"J. Comput. Mol. Des."},{"doi-asserted-by":"crossref","unstructured":"(2017). Schr\u00f6dinger Release 2017-2: Epik, Schr\u00f6dinger, LLC.","key":"ref_46","DOI":"10.2307\/j.ctvcm4h07.63"},{"doi-asserted-by":"crossref","unstructured":"(2017). Schr\u00f6dinger Release 2017-2: QikProp, Schr\u00f6dinger, LLC.","key":"ref_47","DOI":"10.2307\/j.ctvcm4h07.63"},{"doi-asserted-by":"crossref","unstructured":"(2017). Schr\u00f6dinger Release 2017-2: MacroModel, Schr\u00f6dinger, LLC.","key":"ref_48","DOI":"10.2307\/j.ctvcm4h07.63"},{"unstructured":"(2015). M07-A10: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Clinical and Laboratory Standards Institute. [10th ed.].","key":"ref_49"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1021\/acs.jnatprod.9b00317","article-title":"Natural Alkaloid Berberine Activity against Pseudomonas aeruginosa MexXY-Mediated Aminoglycoside Resistance: In Silico and in Vitro Studies","volume":"82","author":"Laudadio","year":"2019","journal-title":"J. Nat. Prod."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/1534735419866908","article-title":"Bioactive Immunomodulatory Compounds: A Novel Combinatorial Strategy for Integrated Medicine in Oncology? BAIC Exposure in Cancer Cells","volume":"18","author":"Corradetti","year":"2019","journal-title":"Integr. Cancer Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7037\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:13:17Z","timestamp":1760177597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":51,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21197037"],"URL":"https:\/\/doi.org\/10.3390\/ijms21197037","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2020,9,24]]}}}